SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

March 12, 2024

https://www.globenewswire.com/news-release/2024/03/12/2844531/0/en/SeaStar-Medical-Provides-Updates-on-Enrollment-of-Adult-Pivotal-Clinical-Study-and-Commercial-Launch-of-Quelimmune-FDA-Approved-in-Pediatric-Patients.html

Company plans to hold a business update conference call in April

DENVER, March 12, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq:ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.